ZW-1266 is a cell-permeable deazaflavin analog (Fig. 6d) that selectively inhibits TDP2, but not TDP1 enzymatic activity in vitro, and strongly sensitizes cancer cells toward the treatment of ETP, a phenotype consistent with the TDP2 function loss and leads to the Top2cc formation51. Here, TDP1 is linked to cancer.